title: Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients.
abstract: Highly active antiretroviral therapy improves survival and growth in children with HIV infection. However, its use can be associated with adverse changes in body composition and metabolism. Bone mineral density can be adversely affected in HIV-positive children due to nutritional compromise or certain antiretrovirals. HIV-associated lipodystrophy, consisting of redistribution of adipose tissue, insulin resistance, and dyslipidemia, has also been described in children. Pediatric HIV patients may be at greater risk for these problems because of their longer potential lifetime exposure to these agents and because childhood is normally a period of rapid growth and tissue accretion. Healthcare providers for children with HIV infection must be aware of the potential complications associated with HIV antiretrovirals so that their antiviral efficacy can be balanced against their risk for side effects. In this review, we discuss the alterations in childhood growth and body composition that occur in HIV-infected children, and describe the impact of antiretroviral therapy on these outcomes. The problem of HIV-associated lipodystrophy syndrome in children is also discussed. Children with HIV should have their growth and body composition systematically monitored. Antiretroviral regimens should be tailored to optimize adherence and viral suppression while minimizing the potential for adverse side effects.
authors.affiliation: Division of Endocrinology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA. kimr@email.chop.edu
authors.forename: Roy J
authors.initials: RJ
authors.lastname: Kim
authors.forename: Richard M
authors.initials: RM
authors.lastname: Rutstein
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001823:Body Composition / Q000187:drug effects*; D002648:Child; D048788:Growth and Development / Q000187:drug effects*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000150:complications / Q000378:metabolism / Q000503:physiopathology; D006801:Humans
chemical_list: D019380:Anti-HIV Agents